If you have been reading about Chelation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Copper content is measured separately by techniques such as inductively coupled plasma mass spectrometry or atomic absorption. Amino acid analysis confirms the peptide sequence after hydrolysis. Because the metal and the peptide can be quantified independently, a complete certificate of analysis normally reports both values rather than a single purity figure. This separation of measurements is important when comparing suppliers.
Solid GHK-Cu appears as a blue to blue-violet powder, and the colour is a direct consequence of copper coordination. The complex dissolves readily in water and in many polar solvents, while the free peptide behaves differently. Solubility in nonpolar media is low, which limits its use in oil-based systems. Solutions are typically prepared fresh because the dissolved form is more exposed to hydrolysis and to loss of the metal ion than the dry powder. Working concentrations are usually low, and preparation notes often specify the solvent and the order of addition.
| Property | Value | Notes |
|---|---|---|
| Copper binding sites | Imidazole, amino, and amide nitrogens | Form chelate rings with Cu(II) |
| Conditional binding constant | Reported near 10^16 at neutral pH | Value depends on method and medium |
| Visible absorption | Broad band in the blue-violet region | Source of the characteristic color |
| Common analytical methods | LC-MS, HPLC, UV-Vis, ICP-OES | Used for identity and copper content |
| Main degradation routes | Oxidation, photolysis, hydrolysis | Accelerated by light, heat, and pH extremes |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
=== Medical Student Training in Aging Research (MSTAR) === The University of Texas Medical Student Training in Aging Research (UT-MSTAR) is an NIH-funded T35 short-term research training program administered by the Barshop Institute and supported by the National Institute on Aging. Established in 2025, the program is directed by Elena Volpi, MD, PhD, FGSA, and represents a unique statewide collaboration among the four largest medical schools in The University of Texas System: UT Health San Antonio, UTHealth Houston, UT Medical Branch, and UT Southwestern Medical Center. The program was created to address the growing national need for physician-scientists with expertise in aging research and geriatric medicine by introducing medical students to aging research early in their professional training. UT-MSTAR provides approximately 20 first-year medical students each year with an intensive eight-week summer research experience under the mentorship of accomplished investigators conducting basic, translational, clinical, behavioral, and population-based aging research. Students are paired with faculty mentors whose research encompasses the biology of aging, geroscience, Alzheimer's disease and related dementias, cardiovascular disease, metabolic disorders, frailty, sarcopenia, health disparities, and other age-related conditions.
== External links == Shodex Worldwide and Asia general website Shodex North and Latin America website Shodex Europe, Middle East, Africa website Showa Denko Develops New Shodex™ Analytical Column Resonac Website about Shodex HPLC columns
== B == bacillary band – bacteria – bacteriochlorin – bark – Barr body – basal body – basal metabolic rate – base – base pair – basement membrane – basidiomycetes – basidium – B cell – benthic zone – beta sheet – binary fission – binding site – bioassay – biodiversity – bioenergetics – biogeochemical cycle – biological magnification – bioluminescence – biome – biopolymer – biosphere – blood – blood–brain barrier – blotting – bond energy – book lung – botany – bottleneck effect – Bowman capsule – brain stem – bronchiole – Brønsted acid – Brønsted base – Brownian movement – bryophyte – bubonic plague – budding – bulk flow
==== United States ==== TMA-2 is not an explicitly controlled substance in the United States. However, it is a positional isomer of 3,4,5-trimethoxyamphetamine (TMA), and thus may be considered a Schedule I controlled substance in this country similarly to TMA.
=== Colitis === Clostridioides difficile colitis may occur in connection with the use of any antibacterial drug, especially those with a broad spectrum of activity such as clindamycin, cephalosporins, and fluoroquinolones. Fluoroquinoline treatment is associated with risk that is similar to or less than that associated with broad spectrum cephalosporins. Fluoroquinolone administration may be associated with the acquisition and outgrowth of a particularly virulent Clostridium strain.
Sources: en.wikipedia.org
Darkling Beetle/Mealworm Information. Center for Insect Science Education Outreach. University of Arizona. Mealworms and Darkling Beetles (Tenebrio beetle). Archived 2021-04-26 at the Wayback Machine FOSSweb.
Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat metastatic prostate cancer (mPC). To a lesser extent, it is used at high doses for locally advanced prostate cancer (LAPC) as a monotherapy without castration. Bicalutamide was also previously used as monotherapy to treat localized prostate cancer (LPC), but authorization for this use was withdrawn following unfavorable trial findings. Besides prostate cancer, bicalutamide is limitedly used in the treatment of excessive hair growth and scalp hair loss in women, as a puberty blocker and component of feminizing hormone therapy for transgender girls and women, to treat gonadotropin-independent early puberty in boys, and to prevent overly long-lasting erections in men. It is taken by mouth. Common side effects of bicalutamide in men include breast growth, breast tenderness, and hot flashes. Other side effects in men include feminization and sexual dysfunction. Some side effects like breast changes and feminization are minimal when combined with castration. While the medication appears to produce few side effects in women, its use in women is not explicitly approved by the Food and Drug Administration (FDA) at this time. Use during pregnancy may harm the baby. In men with early prostate cancer, bicalutamide monotherapy has been found to increase the likelihood of death from causes other than prostate cancer.
=== N-terminal targeting signals === The N-terminus is the first part of the protein that exits the ribosome during protein biosynthesis. It often contains signal peptide sequences, "intracellular postal codes" that direct delivery of the protein to the proper organelle. The signal peptide is typically removed at the destination by a signal peptidase. The N-terminal amino acid of a protein is an important determinant of its half-life (likelihood of being degraded). This is called the N-end rule.
== CFNA (alternative to Mosher's acid) == A newer chiral derivatizing agent (CDA), α-cyano-α-fluoro (2-naphthyl)-acetic acid (2-CFNA) was prepared in optically pure form by the chiral HPLC separation of a racemic 2-CFNA methyl ester. This ester was obtained by fluorination of methyl α-cyano (2-naphthyl) acetate with FClO3. 2-CFNA has been shown to be a superior CDA than Mosher's agent to determine the enantiomeric excess of a primary alcohol.
Of the ten top-up players, only two (James Kelly and Matt Dea) remained with the club beyond the 2016 season: Kelly played one further season before retiring, and Dea played two more seasons before being delisted.
Sources: en.wikipedia.org
==== Theranostic pairs ==== When two isotopes of an element form a theranostic agent they can be called a theranostic pair, eg. Cu-64 and Cu-67. Cu-64 emits positrons for imaging in PET scans, and Cu-67 is a beta emitter to kill targeted cells.
A mass spectrum is a histogram plot of intensity vs. mass-to-charge ratio (m/z) in a chemical sample, usually acquired using an instrument called a mass spectrometer. Not all mass spectra of a given substance are the same; for example, some mass spectrometers break the analyte molecules into fragments; others observe the intact molecular masses with little fragmentation. A mass spectrum can represent many different types of information based on the type of mass spectrometer and the specific experiment applied. Common fragmentation processes for organic molecules are the McLafferty rearrangement and alpha cleavage. Straight chain alkanes and alkyl groups produce a typical series of peaks: 29 (CH3CH2+), 43 (CH3CH2CH2+), 57 (CH3CH2CH2CH2+), 71 (CH3CH2CH2CH2CH2+) etc.
In physics, cryogenics is the production and behaviour of materials at very low temperatures. The 13th International Institute of Refrigeration's (IIR) International Congress of Refrigeration (held in Washington, DC in 1971) endorsed a universal definition of "cryogenics" and "cryogenic" by accepting a threshold of 120 K (−153.15 °C) to distinguish these terms from conventional refrigeration. This is a logical dividing line, since the normal boiling points of the so-called permanent gases (such as helium, hydrogen, neon, nitrogen, oxygen, and normal air) lie below 120 K, while the Freon refrigerants, hydrocarbons, and other common refrigerants have boiling points above 120 K. Discovery of superconducting materials with critical temperatures significantly above the boiling point of nitrogen has provided new interest in reliable, low-cost methods of producing high-temperature cryogenic refrigeration. The term "high temperature cryogenic" describes temperatures ranging from above the boiling point of liquid nitrogen, −195.79 °C (77.36 K; −320.42 °F), up to −50 °C (223 K; −58 °F). The discovery of superconductive properties is first attributed to Heike Kamerlingh Onnes on 10 July 1908, after they were able to reach a temperature of 2 K. These first superconductive properties were observed in mercury at a temperature of 4.2 K.
=== Ventricular assist device === Collaboration between NASA, Dr. Michael DeBakey, Dr. George Noon, and MicroMed Technology Inc. resulted in a heart pump for patients awaiting heart transplants. The MicroMed DeBakey ventricular assist device (VAD) functions as a "bridge to heart transplant" by pumping blood until a donor heart is available. The pump is approximately one-tenth the size of other currently marketed pulsatile VADs. Because of the pump's small size, fewer patients developed device-related infections. It can operate up to 8 hours on batteries, giving patients the mobility to do normal, everyday activities.
Hong Kong and mainland China: There are two border crossings between Hong Kong and mainland China at which border controls imposed by the two jurisdictions are colocated: West Kowloon Railway Station (simplified Chinese: 香港西九龙站; traditional Chinese: 香港西九龍站): A component of the Guangzhou–Shenzhen–Hong Kong Express Rail Link (Chinese: 廣深港高速鐵路; pinyin: Guǎng–Shēn–Gǎng Gāosù Tiělù), West Kowloon Station contains a "Mainland Port Area (simplified Chinese: 站内地口岸区; traditional Chinese: 站內地口岸區)", essentially enabling passengers and goods to clear mainland Chinese immigration on Hong Kong soil. Shenzhen Bay Port (simplified Chinese: 深圳湾口岸; traditional Chinese: 深圳灣口岸): The land border checkpoint at Shenzhen Bay Port in the mainland contains a Hong Kong Port Area (simplified Chinese: 港方口岸区; traditional Chinese: 港方口岸區) which enables passengers and goods to clear Hong Kong border controls in the mainland. The checkpoint is located in mainland China on land leased from the city of Shenzhen in Guangdong province. By enabling travellers to clear both Chinese and Hong Kong border controls at a single location, it eliminates the need for a second checkpoint on the Hong Kong side of the Shenzhen Bay Bridge.
Sources: en.wikipedia.org
It is not approved as a pharmaceutical in major markets and is used mainly as a cosmetic ingredient and a laboratory reagent. Regulatory status varies by country and by the product category in which it appears. Claims about therapeutic effects should be treated separately from permitted cosmetic labeling.
Reversed-phase high-performance liquid chromatography and mass spectrometry are common for the peptide portion. Copper content is usually determined by inductively coupled plasma techniques or by spectrophotometry. Ultraviolet-visible spectroscopy takes advantage of the visible absorption band of the copper complex.
Light, oxygen, and elevated temperature promote degradation of the peptide, and strongly acidic or alkaline conditions accelerate hydrolysis. The copper complex is generally more resistant to oxidation than the free peptide. Storage in a dry, dark, cold environment limits loss over time.
The colour comes from electronic transitions in the coordinated copper(II) ion. Ligand field effects absorb part of the visible spectrum. A colourless or greenish sample may indicate degraded material.